491 related articles for article (PubMed ID: 11078980)
1. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
[TBL] [Abstract][Full Text] [Related]
4. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
al-Maskari M; Gebbie J; Kendall-Taylor P
Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
[TBL] [Abstract][Full Text] [Related]
5. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
6. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
7. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications.
Caron P; Tabarin A; Cogne M; Chanson P; Jaquet P
Eur J Endocrinol; 2000 Jun; 142(6):565-71. PubMed ID: 10822218
[TBL] [Abstract][Full Text] [Related]
8. Results of a two-year treatment with slow release lanreotide in acromegaly.
Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
[TBL] [Abstract][Full Text] [Related]
9. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
Ambrosio MR; Franceschetti P; Bondanelli M; Doga M; Maffei P; Baldelli R; Tamburrano G; Sicolo N; Giustina A; degli Uberti EC
Metabolism; 2002 Mar; 51(3):387-93. PubMed ID: 11887179
[TBL] [Abstract][Full Text] [Related]
12. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
Chanson P; Leselbaum A; Blumberg J; Schaison G
Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
16. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
Caron P; Cogne M; Gusthiot-Joudet B; Wakim S; Catus F; Bayard F
Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
[TBL] [Abstract][Full Text] [Related]
17. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
[TBL] [Abstract][Full Text] [Related]
18. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
19. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
20. Clinical results of long-term slow-release lanreotide treatment of acromegaly.
Giusti M; Ciccarelli E; Dallabonzana D; Delitala G; Faglia G; Liuzzi A; Gussoni G; Giordano Disem G
Eur J Clin Invest; 1997 Apr; 27(4):277-84. PubMed ID: 9134375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
